Kristine E Ensrud, Joseph C Larson1, Katherine A Guthrie1, Carolyn J Crandall2, Andrea Z LaCroix3, Susan D Reed4, Shalender Bhasin5, Caroline M Mitchell6, Hadine Joffe. 1. Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA. 2. Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, CA. 3. Department of Family Medicine and Public Health, University of California-San Diego, La Jolla, CA. 4. Department of Obstetrics and Gynecology, University of Washington, Seattle, WA. 5. Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 6. Department of Obstetrics & Gynecology, Massachusetts General Hospital, Boston, MA.
Abstract
OBJECTIVES: The aim of this study was to quantify changes in serum total estradiol (E2) and estrone (E1) concentrations with initiation of low-dose oral estradiol treatment and evaluate whether changes in concentrations mediate the effect of treatment in reducing vasomotor symptom (VMS) frequency. METHODS: We analyzed baseline and week 8 (W8) data from 171 perimenopausal and postmenopausal women with VMS enrolled in low-dose 17β estradiol ( n = 72) and placebo ( n = 99) groups of a randomized clinical trial. RESULTS: From baseline to W8, women in the low-dose estradiol group had a fourfold increase in E2, resulting in a W8 E2 of 23 pg/mL, and a fivefold increase in E1, resulting in a W8 E1 of 110.7 pg/mL. In contrast, E2 and E1 among women in the placebo group were unchanged from baseline to W8. Changes in E2 and E1 from baseline to W8 met criteria for mediating the effect of low-dose estradiol treatment on VMS frequency. With change in estrogen concentration added to treatment assignment in a regression model predicting W8 VMS frequency, the effect of treatment with low-dose estradiol versus placebo was attenuated, with change in E2 representing a 44.1% reduction ( P = 0.03) and change in E1 representing a 69.5% reduction ( P = 0.02) in total intervention effect. CONCLUSION: Among perimenopausal and postmenopausal women with VMS, treatment with low-dose oral estradiol versus placebo results in four- to fivefold increases in serum E2 and E1. The increases in serum E2 and E1 with low-dose oral estradiol treatment seem to mediate in part the effect of treatment in reducing VMS frequency.
OBJECTIVES: The aim of this study was to quantify changes in serum total estradiol (E2) and estrone (E1) concentrations with initiation of low-dose oral estradiol treatment and evaluate whether changes in concentrations mediate the effect of treatment in reducing vasomotor symptom (VMS) frequency. METHODS: We analyzed baseline and week 8 (W8) data from 171 perimenopausal and postmenopausal women with VMS enrolled in low-dose 17β estradiol ( n = 72) and placebo ( n = 99) groups of a randomized clinical trial. RESULTS: From baseline to W8, women in the low-dose estradiol group had a fourfold increase in E2, resulting in a W8 E2 of 23 pg/mL, and a fivefold increase in E1, resulting in a W8 E1 of 110.7 pg/mL. In contrast, E2 and E1 among women in the placebo group were unchanged from baseline to W8. Changes in E2 and E1 from baseline to W8 met criteria for mediating the effect of low-dose estradiol treatment on VMS frequency. With change in estrogen concentration added to treatment assignment in a regression model predicting W8 VMS frequency, the effect of treatment with low-dose estradiol versus placebo was attenuated, with change in E2 representing a 44.1% reduction ( P = 0.03) and change in E1 representing a 69.5% reduction ( P = 0.02) in total intervention effect. CONCLUSION: Among perimenopausal and postmenopausal women with VMS, treatment with low-dose oral estradiol versus placebo results in four- to fivefold increases in serum E2 and E1. The increases in serum E2 and E1 with low-dose oral estradiol treatment seem to mediate in part the effect of treatment in reducing VMS frequency.
Authors: Kerstin L Edlefsen; Rebecca D Jackson; Ross L Prentice; Imke Janssen; Aleksandar Rajkovic; Mary Jo O'Sullivan; Garnet Anderson Journal: Menopause Date: 2010 May-Jun Impact factor: 2.953
Authors: John F Randolph; MaryFran Sowers; Irina Bondarenko; Ellen B Gold; Gail A Greendale; Joyce T Bromberger; Sarah E Brockwell; Karen A Matthews Journal: J Clin Endocrinol Metab Date: 2005-09-06 Impact factor: 5.958
Authors: Kala Visvanathan; Lisa Gallicchio; Chrissy Schilling; Janice K Babus; Lynn M Lewis; Susan R Miller; Howard Zacur; Jodi A Flaws Journal: Obstet Gynecol Date: 2005-12 Impact factor: 7.661
Authors: Carolyn J Crandall; Joseph C Larson; Kristine E Ensrud; Andrea Z LaCroix; Katherine A Guthrie; Susan D Reed; Shalender Bhasin; Susan Diem Journal: Maturitas Date: 2022-04-25 Impact factor: 5.110
Authors: Susan D Reed; Andrea Z LaCroix; Garnet L Anderson; Kristine E Ensrud; Bette Caan; Janet S Carpenter; Lee Cohen; Susan J Diem; Ellen W Freeman; Hadine Joffe; Joseph C Larson; Susan M McCurry; Caroline M Mitchell; Katherine M Newton; Barbara Sternfeld; Katherine A Guthrie Journal: Menopause Date: 2020-04 Impact factor: 2.953
Authors: William Rosner; Susan E Hankinson; Patrick M Sluss; Hubert W Vesper; Margaret E Wierman Journal: J Clin Endocrinol Metab Date: 2013-03-05 Impact factor: 5.958